

Draft program subject to change
11/02/2020



1st Translational Research Conference
Chronic Lymphocytic Leukaemia
Paris, France
March 20-22, 2020

Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

Friday, March 20, 2020

08:15–08:30 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences

Chair (s): TBA

08:30-08:45	Genetic predisposition	Jennifer Brown (Boston)
08:45-08:50	<i>Discussion</i>	
08:50-09:05	Genetic landscape	Cathy Wu (Boston)
09:05-09:10	<i>Discussion</i>	
09:10-09:25	Ibrutinib	Jennifer Woyach (Columbus)
09:25-09:30	<i>Discussion</i>	
09:30-09:45	Epigenetic landscape	Christopher Oakes (Columbus)
09:45-09:50	<i>Discussion</i>	
09:50-10:05	Risk stratification in CLL: future perspective with focus on complex karyotype and NOTCH1 mutations	Panagiotis Baliakas (Uppsala)
10:05-10:10	<i>Discussion</i>	
10:10-10:40	<i>Panel discussion</i>	
10:40-11:10	<i>Coffee Break</i>	

SESSION II – The role of BCR activation and signalling for CLL

Chair (s): TBA

11:10-11:25	BCR isotypes/autonomous signalling	Hassan Jumaa (Ulm)
11:25-11:30	<i>Discussion</i>	
11:30-11:45	The latest news on stereotypes	Kostas Stamatopoulos (Thessaloniki)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	Novel BCR targets	Andrew Steele (Southampton)
12:05-12:10	<i>Discussion</i>	

12:10-12:25 Next generation BTK inhibitors (covalent/non-covalent?) Anthony Mato (New York)
12:25-12:30 *Discussion*

SHORT ORAL COMMUNICATION

12:30-12:37 *Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression* Pablo Opezzo (Montevideo)

12:37-12:40 *Discussion*

12:40-13:10 *Panel discussion*

13:10-14:50 *Lunch*

**13:30-14:30 SATELLITE SYMPOSIUM:
Utilization of MRD assessment in the clinical management of CLL patients**

Chair: Barbara Eichhorst (Cologne)

Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)

This symposium is organised and funded by Adaptive Biotechnologies.

SESSION III – Therapeutic options for CLL

Chair(s): TBA

14:50-15:05 Ibrutinib for everybody Jennifer Woyach (Columbus)
15:05-15:10 *Discussion*

15:10-15:25 Ibrutinib for a small subgroups only Florence Cymbalista (Bobigny)
15:25-15:30 *Discussion*

15:30-15:45 MURANO and MRD John Seymour (Melbourne)
15:45-15:50 *Discussion*

15:50-16:05 CLL14 update Kirsten Fischer (Cologne)
16:05-16:10 *Discussion*

SHORT ORAL COMMUNICATION

16:10-16:17 *Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies* Scott Best (Portland)

16:17-16:20 *Discussion*

16:20-16:50 *Panel discussion*

16:50-17:20 *Coffee break*

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)

Chair (s): TBA

17:20-17:35 Ibrutinib trials Alessandra Tedeschi (Milan)
17:35-17:40 *Discussion*

17:40-17:55	Ibrutinib real world	George Follows (Cambridge)
17:55-18:00	<i>Discussion</i>	
18:00-18:15	Venetoclax trials	Matthew Davids (Boston)
18:15-18:20	<i>Discussion</i>	
18:20-18:35	Venetoclax / PI3K real world	Anthony Mato (New York)
18:35-18:40	<i>Discussion</i>	

SHORT ORAL COMMUNICATION

18:40-18:47	<i>Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)</i>	Julie von Tresckow (Cologne)
18:47-18:50	<i>Discussion</i>	
18:50-19:20	<i>Panel discussion</i>	
19:20	<i>Get together and poster walks (stand up cocktails and buffet dinner for all)</i>	

Saturday, March 21, 2020

09:00-10:00 Possible slot for a satellite symposium

09:00-10:00 3 Simultaneous Meet the Expert sessions (non-clinical)

- | | |
|--|-----------------------------|
| 1. Prognostic and predictive markers | Barbara Eichhorst (Cologne) |
| 2. Resistance to ibrutinib: what to do | Jennifer Brown (Boston) |
| 3. First line therapy: continuous or time limited treatment? | Michael Hallek (Cologne) |

10:00-10:30 Coffee break

SESSION V – The increasing role of the leukaemic microenvironment

Chair (s): TBA

10:30-10:45	Role of stromal cells	Andrea Brendolan (Milan)
10:45-10:50	<i>Discussion</i>	
10:50-11:05	Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche	Silvia Deaglio (Turin)
11:05-11:10	<i>Discussion</i>	
11:10-11:25	Role of T cells	Arnon Kater (Amsterdam)
11:25-11:30	<i>Discussion</i>	
11:30-11:45	Immunomodulatory effects of kinase inhibitors	Adrian Wiestner (Bethesda)
11:45-11:50	<i>Discussion</i>	

SHORT ORAL COMMUNICATION

11:50-11:57	<i>Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib</i>	Maria Joao Baptista (Badalona)
11:57-12:00	<i>Discussion</i>	

12:00-12:30 *Panel discussion*

12:30-14:10 *Lunch*

13:00-14:00 *Possible slot for a satellite symposium*

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL

Chair (s): TBA

14:10-14:25 Next generation PI3K inhibitors

Peter Hillmen (Leeds)

14:25-14:30 *Discussion*

14:30-14:45 Novel inhibitors at preclinical level
(MCL1 & CDK inhibitors)

Alexey Danilov (Los Angeles)

14:45-14:50 *Discussion*

14:50-15:05 Mechanistic effects of BH3 Mimetics in CLL

Eric Eldering (Amsterdam)

15:05-15:10 *Discussion*

15:10-15:25 CAR-T cells

David Maloney (Seattle)

15:25-15:30 *Discussion*

15:30-15:45 Allo-transplant

Peter Dreger (Heidelberg)

15:45-15:50 *Discussion*

15:50-16:20 *Panel discussion*

16:20-16:50 *Coffee break*

SESSION VII – Efficacy through safety

Chair (s): TBA

16:50-17:05 Cardiologist

Javid Moslehi (Nashville)

17:05-17:10 *Discussion*

17:10-17:25 Dermatologist

Nicole LeBoeuf (Boston)

17:25-17:30 *Discussion*

17:30-17:45 Infectious diseases

Pierluigi Viale (Bologna)

17:45-17:50 *Discussion*

17:50-18:05 Gastroenterology

Stefano Fagioli (Bergamo)

18:05-18:10 *Discussion*

18:10-18:40 *Panel discussion*

Free evening

Sunday, March 22, 2020

07:30-08:30 3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1. Treatment of relapsed CLL

Paolo Ghia (Milan)

2. Management of novel drugs side effect

Carol Moreno (Barcelona)

3. MRD assessment

Andrew Rawstron (Leeds)

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance

Chair (s): TBA

08:40-08:55	Clonal evolution	Davide Rossi (Bellinzona)
08:55-09:00	<i>Discussion</i>	
09:00-09:15	PI3K	Jennifer Brown (Boston)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Venetoclax	John Seymour (Melbourne)
09:35-09:40	<i>Discussion</i>	

SHORT ORAL COMMUNICATIONS

09:40-09:47	<i>Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)</i>	Chiara Pighi (Turin)
09:47-09:50	<i>Discussion</i>	
09:50-09:57	<i>NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia</i>	Stefania Fiorcari (Modena)
09:57-10:00	<i>Discussion</i>	
10:00-10:30	<i>Panel discussion</i>	
10:30-11:00	<i>Coffee break</i>	

SESSION IX – Contrasting therapeutic concepts:

Chair (s): TBA

11:00-11:15	MRD as a dynamic endpoint	Peter Hillmen (Leeds)
11:15-11:20	<i>Discussion</i>	
11:20-11:35	Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL	David M. Kurtz (Stanford)
11:35-11:40	<i>Discussion</i>	
11:40-11:55	Sequential vs combination treatments	Bill Wierda (Houston)
11:55-12:00	<i>Discussion</i>	
12:00-12:15	Time limited vs continuous treatments	Barbara Eichhorst (Cologne)
12:15-12:20	<i>Discussion</i>	
12:20-12:50	<i>Panel discussion</i>	
12:50-13:00	<i>Closing Remarks</i>	

MEETING CLOSURE